Skip to content

Rare Complication After Radiosurgery: Case Report Reveals Risks of Radiation-Induced Cyst Formation

Bilbao, July 3, 2025 – A research team led by Dr. Iñigo L. Sistiaga from the Cruces University Hospital in Spain has documented a rare but serious case of late complications after stereotactic radiosurgery (SRS) for a brain arteriovenous malformation (AVM). The report, published on January 13, 2025, in the Chinese Neurosurgical Journal, describes how a seemingly harmless cyst years after treatment led to a dangerous chronic hematoma. The findings call for a revision of treatment strategies and emphasize the need for long-term follow-up. An AVM is a vascular malformation in which blood flows directly from arteries to veins without passing through the capillary network. This can damage surrounding brain tissue and cause symptoms such as headaches, seizures, or bleeding. SRS, a precise radiation therapy, is considered an effective, non-invasive treatment, especially for AVMs in sensitive brain regions. However, the long-term risks, such as radiation-induced cyst formation (CF) and chronic encapsulated... 

Biocon Biologics Receives EU Approval for Denosumab Biosimilars

  • News

Bengaluru, July 3, 2025 – Biocon Biologics Ltd. (BBL), a leading global biosimilars company and a subsidiary of Biocon Ltd., has achieved a significant success: The European Commission (EC) has granted marketing authorization for the denosumab biosimilars Vevzuo® and Evfraxy® in the European Union. This approval marks an important step in the company's mission to improve access to essential medicines, particularly in the field of bone health. Vevzuo® is approved for the prevention of bone complications in adults with advanced cancer affecting the bones, as well as for the treatment of giant cell tumors (GCT) of bone in adults and skeletally mature adolescents. Evfraxy®, on the other hand, is indicated for the treatment of osteoporosis in postmenopausal women and men, bone loss in men with prostate cancer undergoing hormone ablation, and bone loss due to long-term glucocorticoid therapy. “The approval of Vevzuo and Evfraxy in Europe underscores our scientific expertise and our commitment to better access… 

Prostate Cancer: BKK Pfalz Covers Costs for mpMRI Early Detection

Ludwigshafen, July 3, 2025 – Prostate cancer is the most common cancer in men in Germany, with around 65,000 new cases annually, and the risk increases with age. BKK Pfalz is now setting new standards in early detection by covering the costs of multiparametric magnetic resonance imaging (mpMRI) of the prostate for its insured members. This innovative, radiation-free procedure enables precise diagnostics that detect tumors early and optimize treatment. The mpMRI provides detailed images of the prostate and can accurately locate aggressive tumor sites. It is used when there is suspicion of prostate cancer during screening – for example, due to an elevated PSA value or an abnormal digital rectal examination. “The earlier a tumor is detected, the better the chances of recovery,” emphasizes Thomas Grausam, Head of Customer Relations at BKK Pfalz. “That's why we are pleased that we can offer our insured members access to this innovative diagnostic procedure – also… 

Innovative nanocomposite hydrogel shows promising results in cartilage regeneration for osteoarthritis treatment

  • News

A research team from Northwest University in China has developed a groundbreaking nanocomposite hydrogel system to tackle the dual challenges of inflammation and cartilage damage in osteoarthritis (OA), one of the most common causes of joint disability worldwide. The study, published in Engineering, confirms that the dual-drug-loaded hydrogel promotes cartilage repair through synergistic immunomodulation and chondrocyte differentiation, offering a novel therapeutic strategy for OA. OA is characterized by persistent inflammation and impaired cartilage regeneration, and existing treatments cannot effectively combat both mechanisms. The newly developed HLC(Dex)–SPNs–KGN hydrogel combines two natural proteins – human-like collagen (HLC) and silk protein nanoparticles (SPNs) – to deliver two key molecules: dexamethasone (Dex), an anti-inflammatory glucocorticoid that suppresses early inflammation and polarizes pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages; and kartogenin (KGN), which stimulates the differentiation of human mesenchymal stem cells (hMSCs) into chondrocytes and maintains chondrocyte stability in later stages. The hydrogel design enables...

Alzheimer's protein BACE1 identified as key to preventing lung cancer brain metastases

Hamilton/Cleveland, July 3, 2025 – A groundbreaking discovery by researchers at McMaster University, Cleveland Clinic, and Case Comprehensive Cancer Center could revolutionize the treatment of lung cancer brain metastases. In a study published July 2, 2025, in Science Translational Medicine, they reveal how the protein BACE1, long associated with Alzheimer's disease, promotes the spread of lung cancer to the brain. This finding opens the door to repurposing an existing Alzheimer's drug to fight cancer. Brain metastases, tumors that spread from other parts of the body to the brain, occur in up to 40 percent of patients with non-small cell lung cancer and are difficult to treat. "We've always associated BACE1 with Alzheimer's disease, so it's a significant discovery that it plays a central role in lung cancer brain metastases," says Sheila Singh, the study's lead author, director of the McMaster Centre for Discovery in Cancer Research...

Friedrich Merz as "Lying Chancellor": How empty promises endanger democracy

Friedrich Merz, Chancellor of Germany since May 2025 and chairman of the CDU, is being criticized for being a "Lying Chancellor" whose election promises have proven to be empty. Critics accuse him of undermining citizens' trust in democracy through broken promises in the areas of electricity tax, migration, and new debt. This essay examines the accusations against Merz, analyzes his policies in the aforementioned areas, and shows how his actions endanger democratic structures. It is argued that Merz's deceptions and U-turns weaken political credibility and threaten social cohesion. 1. Broken Promises: Electricity Tax, Migration, and New Debt Electricity Tax In the 2025 election campaign, Merz promised a significant reduction in the electricity tax to relieve citizens in the face of rising energy costs. In an interview with ARD on January 15, 2025, he stated that the electricity tax should be "lowered to the European minimum level" to help households and businesses... 

Witch Hunt 2.0: America's Anti-Communism Paranoia in 2025

Washington, July 3, 2025 – A new wave of anti-communism paranoia is resurfacing in the United States, reminiscent of the McCarthy era of the 1950s. Fueled by political rhetoric, social media, and the polarizing leadership of President Donald Trump, communism is being invoked as a bogeyman, despite posing no real political or societal threat in 2025. This report analyzes the causes of this paranoia, its roots in mass psychology, and why it appears anachronistic in a globalized, digital world. Based on peer-reviewed studies and authentic quotes, it offers a critical look at the dynamics plunging the US into an era of fear and mistrust. The Revival of an Old Enemy The fear of communism is not a new phenomenon in the US. During the McCarthy era (1947–1957), the paranoid search for "communist infiltrators" led to mass persecutions, professional bans, and societal division.… 

Ripple XRP in European Finance – A Breakthrough with Potential for Laboratory Medicine

  • News

Frankfurt/Brussels, July 3, 2025 – The cryptocurrency XRP, developed by Ripple Labs, is experiencing a remarkable upswing in European finance. Through technological innovations, regulatory advancements, and strategic partnerships, XRP is establishing itself as a key player for fast and cost-effective cross-border payments. This breakthrough could also revolutionize European laboratory medicine, particularly by optimizing financial flows in quality assurance, such as in proficiency testing. This report analyzes Ripple's progress and highlights the potential impact on laboratory medicine. Ripple's Breakthrough in European Finance Ripple, founded in 2012 by Arthur Britto, David Schwartz, and Ryan Fugger, specializes in efficient payment solutions. Unlike Bitcoin, which is based on Proof-of-Work, the XRP Ledger uses an energy-efficient consensus mechanism that processes transactions in 3–5 seconds. "RippleNet offers a digital payment platform built on the decentralized ledger database of the XRP Ledger," explains Libertex. XRP serves as a bridge currency, enabling banks and financial institutions to conduct international… 

China's Push into European Laboratory Medicine – Proficiency Testing in Focus

  • News

Beijing/Brussels, July 3, 2025 – China is intensifying its efforts to establish itself in the field of laboratory medicine in Europe, particularly through participation in and the establishment of proficiency testing. These external quality controls, which ensure the accuracy and reliability of laboratory analyses, are a strategic goal that brings both potential and challenges for the European healthcare market. Proficiency Testing: A Pillar of Quality Assurance Proficiency testing involves standardized tests in which laboratories analyze identical samples to verify the comparability and precision of their measurement methods. In Germany, they are mandatory according to the guideline of the German Medical Association (Bundesärztekammer) for the quality assurance of laboratory medical examinations (Rili-BÄK) to ensure patient safety. The Rili-BÄK stipulates that laboratories must regularly participate in proficiency testing, especially for quantitative measurands such as glucose or HbA1c, with participation required quarterly for each measurand. Providers such as INSTAND e.V. and the Reference Institute for Bioanalytics (RfB) dominate… 

FAQ: Proficiency Testing – What Costs Do Medical Practices Incur?

1. What is proficiency testing and why is it relevant for medical practices?Proficiency testing is an external quality control where laboratories or medical practices analyze standardized samples to verify the accuracy and reliability of their laboratory results. It is mandatory for medical practices with their own laboratory to ensure compliance with legal requirements (e.g., Rili-BÄK) and to guarantee patient safety. 2. What costs do medical practices incur through proficiency testing?The costs for proficiency testing consist of several components: 3. How often must proficiency testing be performed?The frequency depends on the requirements of the guideline of the German Medical Association (Rili-BÄK) and the parameters analyzed. Typically, 2–4 proficiency tests per year per parameter are required, e.g., for blood values, coagulation parameters, or microbiological examinations. 4. Are there differences in costs depending on practice size or specialization?Yes, the costs vary: 5. Can the costs for proficiency testing be reimbursed?As a rule, proficiency testing is a self-service of the practice and is…